See more : Mega Corporation Limited (MEGACOR.BO) Income Statement Analysis – Financial Results
Complete financial analysis of Monterey Bio Acquisition Corporation (MTRYW) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Monterey Bio Acquisition Corporation, a leading company in the Shell Companies industry within the Financial Services sector.
- Investeringsforeningen C Worldwide Indien Kl (CWIIA.CO) Income Statement Analysis – Financial Results
- Entero Healthcare Solutions Limited (ENTERO.NS) Income Statement Analysis – Financial Results
- POSCO M-TECH Co., Ltd. (009520.KQ) Income Statement Analysis – Financial Results
- PT Vale Indonesia Tbk (INCO.JK) Income Statement Analysis – Financial Results
- PAVmed Inc. (PAVM) Income Statement Analysis – Financial Results
Monterey Bio Acquisition Corporation (MTRYW)
About Monterey Bio Acquisition Corporation
Monterey Bio Acquisition Corporation focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or related business combination with one or more businesses. It intends to acquire businesses in the biotech industry. The company was formerly known as Chardan FinTech Acquisition Corp. and changed its name to Monterey Bio Acquisition Corporation in April 2021. Monterey Bio Acquisition Corporation was incorporated in 2020 and is based in New York, New York.
| Metric | 2022 | 2021 | 2020 |
|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 2.04M | 0.00 | 0.00 |
| Gross Profit | -2.04M | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% |
| Research & Development | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 522.88K | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 |
| SG&A | 2.04K | 522.88K | 2.40 |
| Other Expenses | 2.04M | 0.00 | 0.00 |
| Operating Expenses | 2.04M | 522.88K | 2.40 |
| Cost & Expenses | 2.04M | 522.88K | 2.40 |
| Interest Income | 881.09 | 2.37K | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 228.49K | 62.72K | 206.30K |
| EBITDA | -2.04M | -522.88K | 0.00 |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% |
| Operating Income | -2.04M | -522.88K | -2.40 |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 881.09K | -60.35K | 0.00 |
| Income Before Tax | -1.16M | -583.23K | -2.40 |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 115.96K | -2.37K | 0.00 |
| Net Income | -1.27M | -580.86K | -2.40 |
| Net Income Ratio | 0.00% | 0.00% | 0.00% |
| EPS | -0.44 | -0.11 | 0.00 |
| EPS Diluted | -0.44 | -0.11 | 0.00 |
| Weighted Avg Shares Out | 2.88M | 5.36M | 2.50K |
| Weighted Avg Shares Out (Dil) | 2.88M | 5.36M | 2.50K |
Source: https://incomestatements.info
Category: Stock Reports